Meropenem therapy in extracorporeal membrane oxygenation patients: an ongoing pharmacokinetic challenge by Patrick M. Honore et al.
Honore et al. Critical Care  (2015) 19:263 
DOI 10.1186/s13054-015-0953-2LETTER Open AccessMeropenem therapy in extracorporeal
membrane oxygenation patients: an
ongoing pharmacokinetic challenge
Patrick M. Honore*, Rita Jacobs, Inne Hendrickx, Elisabeth De Waele, Viola Van Gorp and Herbert D. Spapen
See related commentary by Gonçalves-Pereira and Oliveira, http://ccforum.com/content/18/6/695We agree with the recent commentary of Gonçalves-
Pereira and Oliveira refuting a ‘one size fits all’ paradigm
of antibiotic dosing in patients subjected to extracorporeal
circulation [1] but want to focus somewhat further on
meropenem pharmacokinetics (PK).
Meropenem has optimal bactericidal activity if plasma
levels remain above the minimum inhibitory concentration
of the pathogen for at least 40 % of the dosing interval.
Still, many patients with severe sepsis do not attain
this PK target, have unpredictable PK changes or show
large individual and inter-patient variability in distribution
volume and clearance when treated with recommended
meropenem doses [2, 3].
Meropenem is degraded and significantly sequestered
in the extracorporeal membrane oxygenation (ECMO)
circuit after 4 to 6 h of treatment. ECMO also induces a
systemic inflammatory response which, independently
of underlying sepsis, impairs normal meropenem PK
[4]. Thus, optimization of meropenem treatment during
ECMO requires either more frequent dosing, a dose
increase, or prolonged infusion. Ideally, meropenem should
be infused continuously over 24 h but, due to its relative
instability at room temperature, only a 3-hour infusion is
safely feasible. We suggest to administer a 3-hour infusion
of 2 g meropenem every 6 h [4]. Future adaptations must
be anticipated. We refer to the recently proposed concept
of ‘dose modulation’, which concentrates the largest weight
of antibiotics front-end when the microbial load is highest
and gradually reduces antibiotic dose as sepsis improves
[5]. This would imply increasing the loading dose of
meropenem (4 g?) and ensuring an adequate maintenance
dose guided by PK parameters.* Correspondence: Patrick.Honore@az.vub.ac.be
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